作者
Raoul A Droeser, Christian Hirt, Carsten T Viehl, Daniel M Frey, Christian Nebiker, Xaver Huber, Inti Zlobec, Serenella Eppenberger-Castori, Alexander Tzankov, Raffaele Rosso, Markus Zuber, Manuele Giuseppe Muraro, Francesca Amicarella, Eleonora Cremonesi, Michael Heberer, Giandomenica Iezzi, Alessandro Lugli, Luigi Terracciano, Giuseppe Sconocchia, Daniel Oertli, Giulio C Spagnoli, Luigi Tornillo
发表日期
2013/6/1
期刊
European journal of cancer
卷号
49
期号
9
页码范围
2233-2242
出版商
Pergamon
简介
BACKGROUND
Programmed cell death 1 (PD-1) receptor triggering by PD ligand 1 (PD-L1) inhibits T cell activation. PD-L1 expression was detected in different malignancies and associated with poor prognosis. Therapeutic antibodies inhibiting PD-1/PD-L1 interaction have been developed.
MATERIALS AND METHODS
A tissue microarray (n=1491) including healthy colon mucosa and clinically annotated colorectal cancer (CRC) specimens was stained with two PD-L1 specific antibody preparations. Surgically excised CRC specimens were enzymatically digested and analysed for cluster of differentiation 8 (CD8) and PD-1 expression.
RESULTS
Strong PD-L1 expression was observed in 37% of mismatch repair (MMR)-proficient and in 29% of MMR-deficient CRC. In MMR-proficient CRC strong PD-L1 expression correlated with infiltration by CD8+ lymphocytes (P=0.0001) which did not express PD-1. In …
学术搜索中的文章
RA Droeser, C Hirt, CT Viehl, DM Frey, C Nebiker… - European journal of cancer, 2013